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ABSTRACT
Background:  Gastric cancer poses a significant global 
health burden. It is the second most common cause of 
cancer death worldwide and the ninth leading cause of 
cancer mortality in Zambia, at a rate of 3.8/100,000; 
comparable to USA (2/100,000) and UK (3.4/100,000). 
Survival data on gastric malignancy in Zambia is not 
known.
Objectives: To provide preliminary survival rates of 
pat ients  with his tological ly proven gastr ic  
adenocarcinoma in Zambia.
Study Design: Using our prospective gastric cancer 
research database, we conducted a retrospective audit of 
patients diagnosed with gastric cancer at the University 
Teaching Hospital, Zambia, from June 2010 until January 
2012. We contacted patients or their relatives using phone 
numbers provided at time of enrollment. 
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Main Outcomes: We reviewed age, sex, demographic 
data (income, education), body mass index, symptoms, 
duration of symptoms, treatment (surgery, chemotherapy, 
radiotherapy or combination) and survival outcome. 
Analysis was performed using Kaplan-Meier models and 
log rank test.  
Results: Fifty one patients were diagnosed with gastric 
adenocarcinoma during the study period, but follow-up 
data were available for 50. Median survival was 142 days. 
Age, sex, income, education, BMI, tumor location, and 
treatment modality were not significantly associated with 
overall survival. In Cox regression models, covariates 
associated with survival were a history of regular alcohol 
intake (HR 0.49, 95%CI 0.26,0.92; P=0.025) and 
intestinal type cancer histology (HR 0.40, 95%CI 
0.19,0.83; P=0.01).
Conclusion: Prognosis of newly diagnosed gastric cancer 
in Zambia is poor with significant mortality within 1 year 
of diagnosis, particularly among patients with weight loss 
and dysphagia. 
INTRODUCTION
Gastric cancer is the fourth most common cancer and the 
[1]second most common cause of cancer death worldwide.  
The World Health Organization predicts an increase in 
cancer rates by over 50% over the next 20 years. 
According to GLOBOCAN 2008, the incidence and 
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mortality rate in Zambia, Southern Africa are 4/100,000 
[1]and 3.8/100,000 respectively.   The incidence in USA 
[1]and UK is 4.1/100,000 and 5.5/100,000 respectively.   
The mortality rate is higher in Zambia, 3.8/100,000, 
compared to USA and UK, 2/100,000 and 3.4/100,000 
respectively.  The 5-year survival of gastric cancer in 
[2] [3]USA is 17 %-25%,  similar to the UK at 17 %.   The 
incidence and mortality rates in Zambia are comparable 
to that of USA and UK yet there are no studies regarding 
outcomes and management. In a retrospective study, 
Kelly et al analyzed 2132 upper endoscopy and 
histopathology reports from 1999 to 2005, and reported 
the frequency of gastric cancer to be 5.3%, interestingly 
the incidence in individuals younger than 45 years was 
[4]higher than in USA or UK.   Review of literature shows 
less than 5 published studies regarding gastric cancer in 
[5-7]Zambia  and no studies about management survival out 
comes. 
Some factors that influence survival outcome include 
clinical presentation, patient demographics, cancer 
location, histopathology, stage at diagnosis and 
[8]treatment.   A better understanding of these factors could 
impact management options, increase awareness 
amongst patients and ultimately impact survival 
outcome. The role of clinical presentation, duration of 
symptoms and treatment in gastric cancer outcome in the 
Zambian population has not been studied.  Thus we 
evaluated risk factors associated with gastric cancer 
survival in Zambia.  This data will help establish 
prognostic indicators and guide management.   
METHODS
We have previously reported a case-control study of 
gastric cancer from the Endoscopy Unit of the University 
Teaching Hospital, Lusaka, Zambia. Having 
subsequently been involved in their care and follow-up, 
we report survival data over a two year period. The 
University Teaching Hospital (UTH) is the largest tertiary 
hospital in Zambia, Southern Africa. Gastric cancer cases 
were defined as subjects with histopathologically proven 
gastric cancer.
Data collection
Informed consent was obtained from all patients at time of 
study enrollment. A questionnaire was used to collect 
demographic data (age, gender, occupation, socio-
economic status and education level); a medical history 
was obtained including symptoms, duration, treatment 
modality (surgery, chemotherapy, radiotherapy or 
combination) family and social history (alcohol 
consumption and smoking).  A physical examination was 
performed on all subjects at initial enrollment and body 
mass index (BMI) calculated.  Management was at the 
discretion of the surgical or oncology team. Chart review 
and discussion with patient was used to determine 
treatment plan.  Treatment included surgery, 
chemotherapy, radiation therapy or a combination. 
Information about cancer stage was unavailable for most 
patients because patient financial limitations precluded 
testing for staging or because patients died before 
oncology referral.
Statistical analysis
Stata version 13 (Stata Corp, College Station, TX) was 
used for statistical analysis. Descriptive analysis was 
used to calculate the mean ± standard deviation.  Overall 
survival was calculated as the number of days between 
diagnostic endoscopy and death or censored at last 
follow-up. Cox proportional hazard regression models 
were constructed to describe univariate associations 
between potential determinants of survival and factors 
with P<1.0 or of a priori interest were included in 
multiple regressions models. The association between 
histological type and survival was tested using the log-
rank test and displayed as a Kaplan-Meier plot. 
RESULTS
Fifty one patients were diagnosed with gastric 
adenocarcinoma during the study period. Their mean age 
was 61.7 years ± 15.5 (62% male). One patient was 
excluded because time to death was unknown, leaving 50 
patients to be analyzed. Their demographic 
characteristics and the features of their presenting illness 
are shown in Table 1.  Three patients (6%) were HIV 
positive, but one result was missing. All HIV positive 
patients had a CD4 count below 350 cells/µL. The 
majority of gastric cancers were located in the antrum, 
and most were intestinal adenocarcinoma. Due to 
resource limitations, the majority of patients did not 
receive treatment considered optimal by international 
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standards. However, prompt treatment with chemo-radiotherapy was available and is shown in Table 1. 
Survival is shown in Figure 1. Univariate and multivariate analysis is shown in Table 2.  A history of regular alcohol 
intake was associated with better survival, as was intestinal histology and education. (Table 2, Figure 2).
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Chemotherapy 4 2 1.00
Radiotherapy 4 2 1.00
Conversion $1USD = approximately K5,000
Table 1 Demographic data and Clinical Features
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Variable  Univariate  Multivariate  
 HR  P  HR (95%CI)  P  
Female sex  0.71  0.24  -   
Age under 45 years  0.56  0.12  -   
No education  0.58  0.14  -   
BMI <18.5 kg/m2  0.68  0.24  -   
Gastric atrophy  1.08  0.79  -   
Regular alcohol intake  0.52  0.04  0.49 (0.26,0.92)  0.025  
Dysphagia  2.47  0.07  -   
Vomiting  0.96  0.89  -   
Abdominal  pain  0.84  0.59  -   
Intestinal type histology  0.44  0.02  0.40 (0.19,0.83)  0.01  
Surgery  1.33  0.42  -   
Chemotherapy  0.38  0.07  -   
Radiotherapy  1.49  0.37  -   
 
Table 2: Univariate and multivariate analysis of covariates of survival using Cox regression analysis
HR: hazard ratio. Gastric atrophy was defined as low pepsinogen 1:2 ratio (<4.0). Variables associated (P<0.1) in 
univariate analysis were tested in multivariate analysis.
Figure 1: Overall survival of Zambian patients with 
gastric cancer. Kaplan-Meier plot of survivorship against 















Figure 2: Survivorship (Kaplan-Meier plot) of gastric 
cancer patients according to histological type (Lauren 
classification): intestinal type (n=39) against all other 
types (n=11). P = 0.01 by the log rank test.
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DISCUSSIONS
There are few data on cancer survivorship in Africa. This 
study is limited in size, and data were collected in a 
secondary/tertiary hospital. However, we believe that 
useful conclusions can be drawn. It is clear that there 
were very few patients who might have had resectable 
tumours, and in no case was curative resection attempted. 
Several factors may account for this: late presentation, 
delays in referral within the health service, inexperience 
and reluctance to perform curative surgery, or resource 
constraints. The first line of treatment for gastric 
malignancy is surgery when it is possible, so clearly this 
is a major contributor to poor survival. It is unfortunate 
that the great majority of our patients were unable to 
afford staging investigations, the most important of 
which would be CT scanning or intra-operative 
evaluation. 
In multivariate analysis we found that clinical features 
did not predict survival, and nor did the presence of 
gastric atrophy. Surprisingly, we found no evidence of an 
effect of malnutrition on survival. Only two factors were 
associated with improved survival: a history of alcohol 
intake, and histology (Lauren classification). The adverse 
prognosis of diffuse type cancer and mixed histology is 
not unexpected. However, the observation about alcohol 
is harder to explain. 
The findings in our study suggest a poor prognosis of 
gastric cancer with sate survival within one year of 
diagnosis (30%).  In United Kingdom the one year 
[9]survival is 42.2% in men and 41.7 % in females.  Other 
African countries seem to have a poor overall one year 
[10] [11]survival outcome, Senegal 39.1% , Mali 15.5% , 
[12]Tunisia 7%.   According to the World Health 
Organization, non-communicable diseases are the 
leading cause of global mortality affecting low and 
middle income countries, and projected to surpass 
[13]communicable disease by the year 2030.  Overall global 
cancer rates are expected to increase by 50% over the next 
[14]20 years.  Therefore, it is imperative for further research 
to increase understanding and improve patient outcomes. 
Information regarding gastric cancer within most 
countries in Africa is lacking, primarily due to under-
reporting because of lack of diagnostic resources and 
limited manpower. 
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